Altimmune Inc

NASDAQ:ALTUnited States

Today

Show headlines and story abstract

• DJ Altimmune Initiated at Buy by UBS, from 8 hours ago by Dow Jones

  8 hours ago by Dow Jones
  Companies Mentioned: ALT
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ALT/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 12, 2024 08:57 ET (13:57 GMT)
  

• UBS Initiates Altimmune at Buy With $26 Price Target, from 10 hours ago by MT Newswires

  10 hours ago by MT Newswires
  Companies Mentioned: ALT
  07:07 AM EST, 11/12/2024 (MT Newswires) -- Altimmune (ALT) has an average outperform rating and a price target range of $10 to $28, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major b...

• -- Earnings Flash (ALT) ALTIMMUNE Reports Q3 Revenue $5,000, from 10 hours ago by MT Newswires

  10 hours ago by MT Newswires
  Companies Mentioned: ALT
  07:05 AM EST, 11/12/2024 (MT Newswires) -- ...

• *DJ Altimmune 3Q Loss/Shr 32c >ALT, from 10 hours ago by Dow Jones

  10 hours ago by Dow Jones
  Companies Mentioned: ALT
  
  Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of the IMPACT trial data readout, the timing of the planned End-of-Phase 2 FDA meeting, the timing of the planned IND submissions for pemvidutide, the timing of key milestones for any of our clinical assets, and the prospects for the utility of, regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K and our other filings with the SEC, which are available at www.sec.gov.
  

• Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update, from 10 hours ago by Dow Jones

  10 hours ago by Dow Jones
  Companies Mentioned: ALT
  
  Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of the IMPACT trial data readout, the timing of the planned End-of-Phase 2 FDA meeting, the timing of the planned IND submissions for pemvidutide, the timing of key milestones for any of our clinical assets, and the prospects for the utility of, regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K and our other filings with the SEC, which are available at www.sec.gov.